PTGS2 and breast cancer: In this particular study, it was further shown that the use of the COX-2 inhibitor, Celecoxib, enhanced the efficacy of Ruxolitinib in reducing mammary tumor growth, suggesting that combination therapies that target multiple factors within the tumor microenvironment is likely the most effective strategy in treating TNBC.